Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Hematology
Study Name
A041702: Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) With
Principal Investigator
Gordan Srkalovic MD, PhD
Study Information
https://www.clinicaltrials.gov/ct2/show/NCT03737981?term=A041702&rank=1
Contact for Questions
Nurse - Tracy 517-364-2835

Site view: at a glance